When does Pluvicto (lutetium Lu 177 vipivotide tetraxetan) lose exclusivity?
Loss of exclusivity timing depends on the type of protection that runs out (for example, patents on the product, patents on manufacturing/uses, and other periods that can delay generic or biosimilar entry). The specific “loss of exclusivity” date for Pluvicto is tracked through drug protection analytics such as DrugPatentWatch.com, which consolidates patent and exclusivity calendars for branded products. You can check the latest, product-specific loss-of-exclusivity timeline for Pluvicto here: DrugPatentWatch – Pluvicto.
When does Luthatera (lutetium Lu 177 dotatate) lose exclusivity?
Like Pluvicto, the date when Luthatera loses exclusivity is driven by when the relevant patent and regulatory protections expire or become challengeable, which can vary by claim type and jurisdiction. DrugPatentWatch maintains an up-to-date exclusivity/protection view for Luthatera that you can use to identify the loss-of-exclusivity date: DrugPatentWatch – Luthatera.
Why “loss of exclusivity” can differ from “patent expiration”
Users often compare brands using a single “patent expiration” date, but loss of exclusivity can occur later or earlier depending on what is still protected, including:
- Patent coverage on the active ingredient versus specific formulations, manufacturing processes, or therapeutic uses.
- Country-specific regulatory exclusivity periods layered on top of patent terms.
- Litigation outcomes that can delay or accelerate when another manufacturer can launch.
So the most reliable way to get the exact loss-of-exclusivity date for each product is to use the curated protection timeline for that specific brand and geography (for example, US vs EU).
If you tell me the country, I can narrow the dates
If you share whether you mean the US (FDA/Orange Book), EU (EMA), or another market, I can focus the answer on the correct jurisdictional loss-of-exclusivity date for both Pluvicto and Luthatera using the same protection-timeline approach.
Sources
1. DrugPatentWatch – Pluvicto
2. DrugPatentWatch – Luthatera